Source link : https://www.newshealth.biz/health-news/severe-hypocalcemia-risk-in-dialysis-patients-with-denosumab/
The use of the osteoporosis drug denosumab (Prolia) to prevent fractures associated with advanced chronic kidney disease (CKD) in patients on kidney dialysis significantly increases the risk for potentially life-threatening severe hypocalcemia compared with the use of oral bisphosphonates, prompting the US Food and Drug Administration (FDA) to issue a Boxed Warning regarding the risk. […]
Author : News Health
Publish date : 2024-01-22 11:34:33
Copyright for syndicated content belongs to the linked Source.